Ara
Toplam kayıt 3, listelenen: 1-3
An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy
(CIG Media Group, 2021)
Background To investigate the demographics and treatment details of the myeloma patients who were diagnosed and followed up in Turkey and received up to two lines of therapy. Methods Patients who were recorded on the ...
An interim analysis of the Turkish myeloma registry among the patients who have received up to two lines of therapy
(American Society of Hematology, 2021)
...
Isatuximab in combination with lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma: Updated safety run-in results from the randomized phase 3 ithaca study
(American Society of Hematology, 2022)
Background: Results from a randomized, Phase 3 study by the Spanish Myeloma Group (PETHEMA/GEM) previously showed that treatment with lenalidomide plus dexamethasone (Rd) may delay progression to active disease in patients ...